Article
Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.
Infectious diseases (London, England) - 1 Aug 2015
Lindström Ida, Kjellin Midori, Palanisamy Navaneethan, Bondeson Kåre, Wesslén Lars, Lannergard Anders, Lennerstrand Johan
Abstract excerpt
BACKGROUND: The future treatment of hepatitis C virus (HCV) infection will be combinations of direct-acting antivirals (DAAs) that not only target multiple viral targets, but are also effective against different HCV genotypes. Of the many drug targets in HCV, one promising target is the non-structural 5A protein (NS5A), against which inhibitors, namely daclatasvir, ledipasvir and ombitasvir, have shown potent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.